California completely legalized cannabis for medical and recreational use – promising to spark a $20.2 BILLION industry in the Golden State alone. By getting in on the ground floor of this exceptional opportunity, you could have the chance to pocket life-changing windfalls thanks to this historic event. And one pot stock expert has his sights set on three stocks he expects to skyrocket following this crucial announcement. Get the details here.
A momentous government announcement just changed the face of legal marijuana… forever. California is set to become the largest marijuana market in the world, promising to spark $20.2 billion into this booming industry. Make no mistake: This one historic event could mint the next marijuana millionaires. Click here to learn how to capitalize on this now.
Top 4 Stocks Set to Soar in Feb 2019
If you really want to become a better investor then you need to be looking at where the smart money is heading. You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream.
That’s how the long-term wealth can be found.
In fact, we’ve uncovered four stocks that should have a place in your portfolio immediately.
Small Cap Bargain No. 1—Fate Therapeutics (FATE)
Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors.
We like FATE here following the pullback thanks to two key announcements on its FATE-NK100 treatment for its natural killer cell cancer immunotherapy, and news that the FDA just accepted its investigational new drug (IND) application for FT500 — a potential natural killer cell immunotherapy.
“The safety and clinical benefit observed with a single infusion of FATE-NK100 as a monotherapy in heavily pre-treated cancer patients, including in refractory AML patients that have high leukemic blast burden in the marrow and in advanced solid tumor patients with progressive disease, are encouraging,” said Sarah Cooley, M.D., Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota and the lead investigator of the VOYAGE study.
As things progress for the stock, we strongly believe it could rally to $25, near-term.
Small Cap Bargain No. 2 — New Age Beverage (NBEV)
Cannabis has become the ultimate industry disruptor.
Thanks to growing acceptance, including Canada’s October 2018 legalization, approval for medicinal and recreational usage across the U.S., and growing interest from corporate America.
As cannabis just begins its cultural renaissance, the market could reach $146.4 billion by 2025, according to Grand View Research, from just $7.06 billion in 2016.
It’s just starting to disrupt countless, multi-billion-dollar industries.
The medical community is studying it for a variety of ailments — pain, nausea, loss of appetite, Parkinson’s disease, inflammatory bowel disease, post-traumatic stress disorder, epilepsy, and multiple sclerosis and even traumatic brain injuries — the list goes on.
Cigarette maker Altria just took a 45% stake in Cronos Group, as it seeks to diversity its business, as cigarette smoking falls to its lowest point in history. Alcohol companies like Constellation Brands invested $4 billion in Canopy Growth.
These are good indicators that there is still plenty of room for cannabis opportunities.
Now, there’s potential for further growth and disruption after Congress voted for an $867 billion farm bill with a vote of 386-47 in the House. The Senate approved it with a vote of 87-13. Then, President Trump signed it into law.
One of the things the bill will do is legalize hemp, officially taking if off the Schedule I list and allow it to be “cultivated for any use,” including the production an extraction of cannabidiol, or CBD. Hemp will now be classified as a regular agricultural crop, meaning that U.S. growers can cultivate it and sell it.
Consumers will also begin to see a lot more hemp-derived products on store shelves soon, too. Analysts believe passage could create a multi-billion-dollar opportunity for the CBD market.
“This open the floodgates for this industry to grow very rapidly and scale on a national level,” said Bethany Gomez, director of research for Brightfield Group, as quoted by CNBC.
NBEV could be a winner on the farm bill passage, which now legalizes a lower-THC form of cannabis that can be used to make CBD products.
In response to the Senate’s passage of the bill, New Age issued a statement saying that its CBD products, which include a CBD water, a CBD tea, and a CBD shot, are Farm Bill compliant. Even better, the company is prepared to roll out its CBD products nationally. The company also secured commitments from retailers and distributors at more than 125,000 distribution points, and expects distribution to begin as soon as January.
Small Cap Bargain No. 3 — Energy Fuels Inc. (UUUU)
Energy Fuels Inc. engages in the extraction, recovery, exploration, and sale of uranium in the United States. It operates in two segments, Conventional Uranium and ISR Uranium. The company owns and operates the Nichols Ranch uranium recovery facility located in Wyoming; the Alta Mesa project located in Texas; and the White Mesa Mill located in Utah. It also holds interests in uranium and uranium/vanadium properties and projects in various stages of exploration and evaluation located in Utah, Wyoming, Arizona, New Mexico, and Colorado.
We believe it could double, if not triple with patience.
According to BMO Capital analysts, “Production from top miners will break the trend of rising global uranium inventories following the 2011 Fukushima nuclear disaster and cause the first production deficit in more than a decade… The net result is that uranium has entered a period of structural undersupply and we forecast the beginnings of inventory drawdown, which should continue to provide upward bias to the uranium price as we exit the year.”
In addition, the analysts note, “Chinese nuclear plans are core to the uranium outlook, and BMO anticipates that Beijing will recommit to its longer-term nuclear targets at the upcoming plenary session of the ruling communist party, where economic goals for the next five years are set.”
Small Cap Bargain No. 4 — Cypress Semiconductor (CY)
Cypress Semiconductor designs, develops, manufactures, markets, and sells embedded system solutions worldwide. It operates in two segments, Microcontroller and Connectivity Division and Memory Products Division.
Technically, it’s the most oversold it’s been in quite some time. The last time it was this oversold was September 2017 right before it rallied from $13 to $18.50. We believe it’s overdue for a bounce again now. Not only is it oversold at its lower Bollinger Band (2,20), but RSI, MACD and Williams’ %R are significantly oversold and ready to bounce. In addition, CY has a solid valuations, as well as a dividend of 44 cents. Given the latest pullback, we wouldn’t be surprised to see potential buyout offers.
At current prices of $12.85, fear is out of hand. The pullback is an overreaction.
Again, if you really want to become a better investor then you need to be looking at where the smart money is heading. You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream. We believe we’ve found a good deal of opportunity with the four stocks noted above.
This manual is for informational and entertainment purposes only. The author is not an investment adviser, financial adviser, or broker, and the material contained herein is not intended as investment advice. If you wish to obtain personalized investment advice, you should consult with a Certified Financial Planner (CFP). All statements made in this manual are based on the author’s own opinion. Neither the author or the publisher warrants or assume any responsibility for the accuracy of the statements or information contained in this manual, and specifically disclaims the accuracy of any data, including stock prices and stock performance histories. No mention of a particular security or instrument herein constitutes a recommendation to buy or sell that or any security or instrument, nor does it mean that any particular security, instrument, portfolio of securities, transaction or investment strategy is suitable for any specific individual. Neither the author or the publisher, can assess, verify, or guarantee the accuracy, adequacy, or completeness of any information, the suitability or profitability of any particular investment or methodology, or the potential value of any investment or informational source. READERS BEAR THE SOLE RESPONSIBILITY FOR THEIR OWN INVESTMENT DECISIONS. NEITHER THE AUTHOR OR THE PUBLISHER IS RESPONSIBLE FOR ANY LOSSES DUE TO INVESTMENT DECISIONS MADE BASED ON INFORMATION PROVIDED HEREIN. At the time of writing, neither the author or the publisher has a position in any of the stocks mentioned in this manual. By proceeding with reading this course, you affirm that you have read and understand the above disclaimer.